US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CervoMed

2.63

+0.01000.38%

Post-market: 2.640.0100+0.38%18:05 EDT

Volume:287.82K

Turnover:753.67K

Market Cap:39.76M

PE:-0.82

High:2.65

Open:2.65

Low:2.57

Close:2.62

52wk High:10.89

52wk Low:2.13

Shares:15.12M

Float Shares:9.60M

Volume Ratio:0.72

T/O Rate:3.00%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.1959

EPS(LYR):-2.9824

ROE:-107.62%

ROA:-60.80%

PB:1.73

PE(LYR):-0.88

Loading ...

Overview Company News Filings

Chardan Raises Price Target on CervoMed to $21 From $15, Keeps Buy Rating

MT Newswires Live

CervoMed price target lowered to $11 from $19 at Roth Capital

Chardan Capital Sticks to Their Buy Rating for CervoMed (CRVO)

CervoMed price target raised to $21 from $15 at Chardan

CervoMed Reports 2025 Results, Advances Neflamapimod Programs

CervoMed FY2025 net loss rose 66.67% to USD 27 million

BRIEF-CervoMed Reports Fourth Quarter And Full Year 2025 Financial Results And Provides Corporate Updates

CervoMed: Compelling Neflamapimod Opportunity and Undervalued Shares Despite Near-Term Funding Overhang

CervoMed Q4 EPS $(0.88) Misses $(0.63) Estimate, Sales $8.726M Beat $966.667K Estimate

Benzinga Earnings

Press Release: CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates

CervoMed: Validated Phase 2b Data, De-Risked Pivotal Pathway, and Solid Cash Runway Underpin Reiterated Buy and $25 Target

CervoMed Is Maintained at Buy by D. Boral Capital

CervoMed Inc reports results for the quarter ended December 31 - Earnings Summary

Manufacturing and Formulation Changes Threaten Cervomed’s Neflamapimod Development Timeline and Costs

Cervomed FY2025 net loss widened 66% to USD 26.97 million

Top News Today: Stocks Fall, Oil Prices Rise as Iran Conflict Drags On

Top News Today/Canada: Unemployment Rate Rises to 6.7%

CervoMed Inc expected to post a loss of 72 cents a share - Earnings Preview

CervoMed to present neflamapimod data and host a dementia with Lewy bodies symposium at AD/PD 2026

CervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific Conference

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/CRVO/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CRVO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CRVO\",,,,,undefined,":{"symbol":"CRVO","market":"US","secType":"STK","nameCN":"CervoMed","latestPrice":2.63,"timestamp":1787601600000,"preClose":2.62,"halted":0,"volume":287823,"hourTrading":{"tag":"盘后","latestPrice":2.64,"preClose":2.63,"latestTime":"18:05 EDT","volume":3021,"amount":7941.3401604,"timestamp":1787609122052,"change":0.01,"changeRate":0.003802,"amplitude":0.019011},"delay":0,"changeRate":0.0038167938931296893,"floatShares":9604400,"shares":15119100,"eps":-3.195903,"marketStatus":"Post-Mkt","change":0.01,"latestTime":"08-24 18:05:25 EDT","open":2.65,"high":2.65,"low":2.57,"amount":753665.1299283,"amplitude":0.030534,"askPrice":2.85,"askSize":100,"bidPrice":2.62,"bidSize":8,"shortable":3,"etf":0,"ttmEps":-3.195903,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787616000000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":2.62,"preHourTrading":{"tag":"盘前","latestPrice":2.69,"preClose":2.62,"latestTime":"09:27 EDT","volume":3352,"amount":8832.743578399999,"timestamp":1787578067774,"change":0.07,"changeRate":0.026718,"amplitude":0.034237},"postHourTrading":{"tag":"盘后","latestPrice":2.64,"preClose":2.63,"latestTime":"18:05 EDT","volume":3021,"amount":7941.3401604,"timestamp":1787609122052,"change":0.01,"changeRate":0.003802,"amplitude":0.019011},"volumeRatio":0.724639},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CRVO\",,,,,undefined,":{"symbol":"CRVO","floatShares":9604400,"roa":"-60.80%","roe":"-107.62%","lyrEps":-2.982424,"volumeRatio":0.724639,"shares":15119100,"dividePrice":0,"high":2.65,"amplitude":0.030534,"preClose":2.62,"low":2.57,"week52Low":2.13,"pbRate":"1.73","psRate":"120.02","week52High":10.89,"institutionHeld":0,"latestPrice":2.63,"committee":-0.851852,"eps":-3.195903,"divideRate":0,"volume":287823,"delay":0,"ttmEps":-3.195903,"open":2.65,"prevYearClose":7.9,"prevWeekClose":2.62,"prevMonthClose":2.58,"prevQuarterClose":3.1,"fiveDayClose":2.61,"twentyDayClose":2.66,"sixtyDayClose":3.14},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CRVO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"CRVO","fiscalQuarterEnding":"2026/06","expectedEps":-0.87,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"post","actualEps":-0.64},{"market":"US","date":"2026-05-15","symbol":"CRVO","fiscalQuarterEnding":"2026/03","expectedEps":-0.9,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778817600000,"reportTimeType":"pre","actualEps":-0.86},{"market":"US","date":"2026-03-13","symbol":"CRVO","fiscalQuarterEnding":"2025/12","expectedEps":-0.79,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1773374400000,"reportTimeType":"post","actualEps":-0.88},{"market":"US","date":"2025-11-07","symbol":"CRVO","fiscalQuarterEnding":"2025/09","expectedEps":-0.68,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1762491600000,"reportTimeType":"post","actualEps":-0.84},{"market":"US","date":"2025-08-08","symbol":"CRVO","fiscalQuarterEnding":"2025/06","expectedEps":-0.57,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1754625600000,"reportTimeType":"pre","actualEps":-0.7}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CRVO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CRVO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":6,"updateTime":1766116800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CRVO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CRVO","date":"2026-08-21","current":-0.8198,"percent":0.94197,"low":-119.682483,"twenty":-34.018436,"median":-4.117333,"eighty":-1.548892,"high":-0.69356,"avg":-16.779315,"sd":23.268507,"marketCap":38704885},"quantilePoints":[{"date":"2023-09-01","current":-5.788607,"twenty":-5.849231,"median":-5.813052,"eighty":-5.769051,"marketCap":33591560},{"date":"2023-09-08","current":-5.135433,"twenty":-5.817941,"median":-5.700604,"eighty":-4.975855,"marketCap":29801161},{"date":"2023-09-15","current":-4.791246,"twenty":-5.769051,"median":-5.182368,"eighty":-4.935961,"marketCap":27803825},{"date":"2023-09-22","current":-4.51746,"twenty":-5.708427,"median":-5.1589,"eighty":-4.822536,"marketCap":26215035},{"date":"2023-09-29","current":-4.66902,"twenty":-5.505043,"median":-5.045475,"eighty":-4.536234,"marketCap":27094543},{"date":"2023-10-06","current":-5.250814,"twenty":-5.262548,"median":-5.040586,"eighty":-4.536234,"marketCap":30470722},{"date":"2023-10-13","current":-6.893527,"twenty":-5.817941,"median":-5.065031,"eighty":-4.595684,"marketCap":40003462},{"date":"2023-10-20","current":-8.995809,"twenty":-6.690143,"median":-5.197035,"eighty":-4.691783,"marketCap":52203100},{"date":"2023-10-27","current":-9.201148,"twenty":-7.153624,"median":-5.22148,"eighty":-4.714546,"marketCap":53394692},{"date":"2023-11-03","current":-8.379791,"twenty":-8.309389,"median":-5.27037,"eighty":-4.77036,"marketCap":48628322},{"date":"2023-11-10","current":-9.709606,"twenty":-8.530373,"median":-5.764162,"eighty":-4.78929,"marketCap":56345302},{"date":"2023-11-17","current":-41.851906,"twenty":-9.287195,"median":-5.866832,"eighty":-4.791246,"marketCap":55950767},{"date":"2023-11-24","current":-43.761983,"twenty":-9.977525,"median":-6.385068,"eighty":-4.83818,"marketCap":58504301},{"date":"2023-12-01","current":-41.597229,"twenty":-22.855354,"median":-7.177091,"eighty":-4.969206,"marketCap":55610296},{"date":"2023-12-08","current":-37.39506,"twenty":-39.737313,"median":-7.68555,"eighty":-5.041564,"marketCap":49992521},{"date":"2023-12-15","current":-37.352614,"twenty":-39.16082,"median":-8.389569,"eighty":-5.054275,"marketCap":49935776},{"date":"2023-12-22","current":-28.736045,"twenty":-38.685423,"median":-8.477572,"eighty":-5.063075,"marketCap":38416500},{"date":"2023-12-29","current":-26.825968,"twenty":-38.401034,"median":-8.868694,"eighty":-5.079111,"marketCap":35862966},{"date":"2024-01-05","current":-39.899383,"twenty":-38.549596,"median":-9.044699,"eighty":-5.121353,"marketCap":53340488},{"date":"2024-01-12","current":-39.88198,"twenty":-39.488419,"median":-9.670494,"eighty":-5.172981,"marketCap":53317222},{"date":"2024-01-19","current":-38.625999,"twenty":-39.313626,"median":-10.04206,"eighty":-5.199968,"marketCap":51638132},{"date":"2024-01-26","current":-38.965567,"twenty":-39.313626,"median":-10.775414,"eighty":-5.223436,"marketCap":52092093},{"date":"2024-02-02","current":-34.593614,"twenty":-39.237223,"median":-27.727949,"eighty":-5.242992,"marketCap":46247338},{"date":"2024-02-09","current":-43.719537,"twenty":-39.237223,"median":-28.736045,"eighty":-5.262548,"marketCap":58447556},{"date":"2024-02-16","current":-68.677874,"twenty":-39.888941,"median":-31.961952,"eighty":-5.505043,"marketCap":91813733},{"date":"2024-02-23","current":-59.169936,"twenty":-40.466999,"median":-34.275268,"eighty":-5.692782,"marketCap":79102808},{"date":"2024-03-01","current":-63.372175,"twenty":-41.597229,"median":-35.401364,"eighty":-5.759273,"marketCap":84720676},{"date":"2024-03-08","current":-73.849585,"twenty":-41.945287,"median":-36.142899,"eighty":-5.808163,"marketCap":98727664},{"date":"2024-03-15","current":-76.245081,"twenty":-43.210183,"median":-36.501144,"eighty":-5.849231,"marketCap":101930142},{"date":"2024-03-22","current":-103.758666,"twenty":-50.901256,"median":-37.320992,"eighty":-6.027192,"marketCap":138712367},{"date":"2024-03-28","current":-90.558053,"twenty":-57.709789,"median":-37.373837,"eighty":-6.291199,"marketCap":121064797},{"date":"2024-04-05","current":-61.481111,"twenty":-59.566286,"median":-37.479952,"eighty":-6.48676,"marketCap":133529165},{"date":"2024-04-12","current":-71.595379,"twenty":-59.997513,"median":-38.212361,"eighty":-6.942417,"marketCap":155496070},{"date":"2024-04-19","current":-71.737433,"twenty":-62.930842,"median":-38.413768,"eighty":-7.153624,"marketCap":155804594},{"date":"2024-04-26","current":-94.969175,"twenty":-65.856384,"median":-38.647222,"eighty":-7.237715,"marketCap":206260987},{"date":"2024-05-03","current":-91.738931,"twenty":-67.584491,"median":-38.965567,"eighty":-7.396119,"marketCap":199245307},{"date":"2024-05-10","current":-90.826862,"twenty":-70.379394,"median":-39.220244,"eighty":-7.806798,"marketCap":197264409},{"date":"2024-05-17","current":-48.426621,"twenty":-71.185147,"median":-39.390029,"eighty":-8.309389,"marketCap":201061130},{"date":"2024-05-24","current":-37.632017,"twenty":-70.941929,"median":-39.252477,"eighty":-8.383702,"marketCap":156243317},{"date":"2024-05-31","current":-37.651896,"twenty":-70.600999,"median":-39.231253,"eighty":-8.399347,"marketCap":156325854},{"date":"2024-06-07","current":-38.148885,"twenty":-69.492975,"median":-39.142864,"eighty":-8.458016,"marketCap":158389289},{"date":"2024-06-14","current":-37.791053,"twenty":-68.677874,"median":-39.132924,"eighty":-8.477572,"marketCap":156903616},{"date":"2024-06-21","current":-39.600094,"twenty":-68.284435,"median":-39.132924,"eighty":-8.688778,"marketCap":164414520},{"date":"2024-06-28","current":-34.033815,"twenty":-67.93606,"median":-39.122984,"eighty":-8.944963,"marketCap":141304045},{"date":"2024-07-05","current":-30.813326,"twenty":-67.00636,"median":-39.083225,"eighty":-9.025143,"marketCap":127932985},{"date":"2024-07-12","current":-31.707906,"twenty":-66.374913,"median":-38.90211,"eighty":-9.138568,"marketCap":131647168},{"date":"2024-07-19","current":-32.304293,"twenty":-66.254136,"median":-38.668445,"eighty":-9.459288,"marketCap":134123291},{"date":"2024-07-26","current":-27.89103,"twenty":-66.009803,"median":-38.625997,"eighty":-9.678316,"marketCap":115799986},{"date":"2024-08-02","current":-21.131978,"twenty":-65.799563,"median":-38.413768,"eighty":-9.715473,"marketCap":87737266},{"date":"2024-08-09","current":-18.460659,"twenty":-64.992694,"median":-38.255401,"eighty":-10.106595,"marketCap":93102198},{"date":"2024-08-16","current":-29.88401,"twenty":-63.82037,"median":-38.148885,"eighty":-10.558342,"marketCap":150713310},{"date":"2024-08-23","current":-26.709039,"twenty":-63.123956,"median":-37.878225,"eighty":-10.740213,"marketCap":134701053},{"date":"2024-08-30","current":-30.47318,"twenty":-62.875574,"median":-37.791053,"eighty":-10.88395,"marketCap":153684657},{"date":"2024-09-06","current":-23.484969,"twenty":-62.310952,"median":-37.632017,"eighty":-13.958048,"marketCap":118441183},{"date":"2024-09-13","current":-28.656572,"twenty":-61.520597,"median":-37.39506,"eighty":-19.017097,"marketCap":144523004},{"date":"2024-09-20","current":-27.560062,"twenty":-60.889782,"median":-37.352614,"eighty":-20.363844,"marketCap":138992998},{"date":"2024-09-27","current":-24.761504,"twenty":-59.992238,"median":-37.044217,"eighty":-21.696558,"marketCap":124879101},{"date":"2024-10-04","current":-23.484969,"twenty":-59.885067,"median":-36.618159,"eighty":-21.737099,"marketCap":118441183},{"date":"2024-10-11","current":-22.093874,"twenty":-59.702244,"median":-36.256014,"eighty":-21.195966,"marketCap":111425503},{"date":"2024-10-18","current":-23.40314,"twenty":-59.499033,"median":-36.121676,"eighty":-21.422875,"marketCap":118028496},{"date":"2024-10-25","current":-22.42119,"twenty":-59.246339,"median":-35.506843,"eighty":-21.041389,"marketCap":113076251},{"date":"2024-11-01","current":-20.964631,"twenty":-58.949205,"median":-34.593614,"eighty":-21.041389,"marketCap":105730422},{"date":"2024-11-08","current":-20.522754,"twenty":-58.467774,"median":-33.995368,"eighty":-20.604583,"marketCap":103501912},{"date":"2024-11-15","current":-7.440484,"twenty":-58.205855,"median":-32.960319,"eighty":-20.319817,"marketCap":88892790},{"date":"2024-11-22","current":-6.632186,"twenty":-57.268349,"median":-31.876883,"eighty":-19.75356,"marketCap":79235913},{"date":"2024-11-29","current":-7.461209,"twenty":-55.646905,"median":-31.638328,"eighty":-10.811593,"marketCap":89140402},{"date":"2024-12-06","current":-8.228056,"twenty":-54.314096,"median":-31.509111,"eighty":-9.711562,"marketCap":98302055},{"date":"2024-12-13","current":-1.31262,"twenty":-52.81792,"median":-30.753634,"eighty":-9.005587,"marketCap":15682107},{"date":"2024-12-20","current":-1.540602,"twenty":-48.999152,"median":-30.455494,"eighty":-8.411081,"marketCap":18405842},{"date":"2024-12-27","current":-1.658046,"twenty":-48.426621,"median":-29.978384,"eighty":-8.228056,"marketCap":19808978},{"date":"2025-01-03","current":-1.609687,"twenty":-47.997222,"median":-29.785815,"eighty":-7.657262,"marketCap":19231216},{"date":"2025-01-10","current":-1.457699,"twenty":-47.144687,"median":-29.245398,"eighty":-7.393795,"marketCap":17415393},{"date":"2025-01-17","current":-1.457699,"twenty":-44.916349,"median":-28.653863,"eighty":-7.183487,"marketCap":17415393},{"date":"2025-01-24","current":-1.59587,"twenty":-43.761983,"median":-28.638191,"eighty":-7.010773,"marketCap":19066141},{"date":"2025-01-31","current":-1.561327,"twenty":-43.745005,"median":-28.566935,"eighty":-6.6764,"marketCap":18653454},{"date":"2025-02-07","current":-1.526784,"twenty":-43.24863,"median":-27.889204,"eighty":-6.348881,"marketCap":18240767},{"date":"2025-02-14","current":-1.609687,"twenty":-42.503822,"median":-27.789183,"eighty":-5.849231,"marketCap":19231216},{"date":"2025-02-21","current":-1.575144,"twenty":-42.386727,"median":-27.612716,"eighty":-5.677137,"marketCap":18818529},{"date":"2025-02-28","current":-1.54751,"twenty":-42.123561,"median":-27.159099,"eighty":-5.235169,"marketCap":18488379},{"date":"2025-03-07","current":-1.526784,"twenty":-42.013202,"median":-26.709039,"eighty":-5.079111,"marketCap":18240767},{"date":"2025-03-14","current":-4.449091,"twenty":-41.962266,"median":-26.52242,"eighty":-4.902715,"marketCap":53154092},{"date":"2025-03-21","current":-7.633919,"twenty":-41.885863,"median":-26.463551,"eighty":-4.893488,"marketCap":124361854},{"date":"2025-03-28","current":-5.06435,"twenty":-41.817949,"median":-26.005308,"eighty":-4.799924,"marketCap":82501776},{"date":"2025-04-04","current":-5.919092,"twenty":-41.665143,"median":-25.710723,"eighty":-4.841604,"marketCap":96426126},{"date":"2025-04-11","current":-4.538149,"twenty":-41.597229,"median":-25.473418,"eighty":-4.783424,"marketCap":73929597},{"date":"2025-04-17","current":-5.235298,"twenty":-41.597229,"median":-25.219748,"eighty":-4.791246,"marketCap":85286646},{"date":"2025-04-25","current":-4.61561,"twenty":-41.512337,"median":-24.761504,"eighty":-4.727795,"marketCap":75191492},{"date":"2025-05-02","current":-5.475694,"twenty":-41.298141,"median":-24.40964,"eighty":-4.781468,"marketCap":89202869},{"date":"2025-05-09","current":-4.535478,"twenty":-40.703923,"median":-23.894115,"eighty":-4.754506,"marketCap":73886084},{"date":"2025-05-16","current":-4.092569,"twenty":-40.111614,"median":-23.509518,"eighty":-4.701084,"marketCap":76409872},{"date":"2025-05-23","current":-3.924764,"twenty":-39.899383,"median":-23.40314,"eighty":-4.546794,"marketCap":73276893},{"date":"2025-05-30","current":-3.631106,"twenty":-39.899383,"median":-22.993995,"eighty":-4.534221,"marketCap":67794181},{"date":"2025-06-06","current":-3.514575,"twenty":-39.885461,"median":-22.735979,"eighty":-4.503786,"marketCap":65618501},{"date":"2025-06-13","current":-3.551865,"twenty":-39.7837,"median":-22.503019,"eighty":-4.258784,"marketCap":66314718},{"date":"2025-06-20","current":-3.258207,"twenty":-39.75913,"median":-22.404825,"eighty":-4.158521,"marketCap":60832005},{"date":"2025-06-27","current":-3.311811,"twenty":-39.663708,"median":-22.077508,"eighty":-4.077653,"marketCap":61832818},{"date":"2025-07-03","current":-2.633601,"twenty":-39.550025,"median":-21.823837,"eighty":-3.980044,"marketCap":49170362},{"date":"2025-07-11","current":-3.360754,"twenty":-39.440965,"median":-21.455606,"eighty":-3.896797,"marketCap":62746603},{"date":"2025-07-18","current":-3.528559,"twenty":-39.386585,"median":-21.072854,"eighty":-3.646022,"marketCap":65879582},{"date":"2025-07-25","current":-3.752298,"twenty":-39.349611,"median":-20.964631,"eighty":-3.646022,"marketCap":70056887},{"date":"2025-08-01","current":-3.845523,"twenty":-39.3019,"median":-20.547303,"eighty":-3.685176,"marketCap":71797431},{"date":"2025-08-08","current":-4.353598,"twenty":-39.293948,"median":-20.408193,"eighty":-3.727127,"marketCap":81283395},{"date":"2025-08-15","current":-4.169718,"twenty":-39.274289,"median":-19.933584,"eighty":-3.76778,"marketCap":94285206},{"date":"2025-08-22","current":-3.772796,"twenty":-39.254519,"median":-19.688096,"eighty":-3.760497,"marketCap":85310069},{"date":"2025-08-29","current":-3.813716,"twenty":-39.233455,"median":-10.865861,"eighty":-3.760497,"marketCap":86235341},{"date":"2025-09-05","current":-4.177901,"twenty":-39.220244,"median":-10.526074,"eighty":-3.773614,"marketCap":94470260},{"date":"2025-09-12","current":-3.764612,"twenty":-39.204768,"median":-9.709606,"eighty":-3.773614,"marketCap":85125014},{"date":"2025-09-19","current":-3.314496,"twenty":-39.138888,"median":-9.122923,"eighty":-3.737606,"marketCap":74947023},{"date":"2025-09-26","current":-3.199921,"twenty":-39.116968,"median":-8.741579,"eighty":-3.623336,"marketCap":72356262},{"date":"2025-10-03","current":-3.34314,"twenty":-39.09097,"median":-8.428681,"eighty":-3.551865,"marketCap":75594714},{"date":"2025-10-10","current":-3.494542,"twenty":-39.075273,"median":-8.291789,"eighty":-3.534152,"marketCap":79018220},{"date":"2025-10-17","current":-3.109897,"twenty":-39.027886,"median":-7.962078,"eighty":-3.498549,"marketCap":70320664},{"date":"2025-10-24","current":-2.897115,"twenty":-38.940184,"median":-7.633919,"eighty":-3.482878,"marketCap":65509250},{"date":"2025-10-31","current":-2.909391,"twenty":-38.804612,"median":-7.450846,"eighty":-3.374238,"marketCap":65786832},{"date":"2025-11-07","current":-2.983046,"twenty":-38.663931,"median":-7.254628,"eighty":-3.361323,"marketCap":67452321},{"date":"2025-11-14","current":-2.621936,"twenty":-38.6419,"median":-7.20399,"eighty":-3.333221,"marketCap":67082212},{"date":"2025-11-21","current":-3.258434,"twenty":-38.625998,"median":-7.137979,"eighty":-3.315314,"marketCap":83366998},{"date":"2025-11-28","current":-3.594765,"twenty":-38.625995,"median":-6.963795,"eighty":-3.314496,"marketCap":91972026},{"date":"2025-12-05","current":-3.276516,"twenty":-38.456214,"median":-6.708179,"eighty":-3.314142,"marketCap":83829634},{"date":"2025-12-12","current":-2.961884,"twenty":-38.413768,"median":-6.632186,"eighty":-3.290836,"marketCap":75779768},{"date":"2025-12-19","current":-2.857006,"twenty":-38.350099,"median":-6.354912,"eighty":-3.258434,"marketCap":73096480},{"date":"2025-12-26","current":-3.066761,"twenty":-38.300453,"median":-6.221623,"eighty":-3.198527,"marketCap":78463057},{"date":"2026-01-02","current":-2.857006,"twenty":-38.248873,"median":-6.028218,"eighty":-3.184173,"marketCap":73096480},{"date":"2026-01-09","current":-2.846157,"twenty":-38.210281,"median":-5.866832,"eighty":-3.139814,"marketCap":72818898},{"date":"2026-01-16","current":-2.560456,"twenty":-38.170115,"median":-5.764162,"eighty":-3.103963,"marketCap":65509250},{"date":"2026-01-23","current":-2.379633,"twenty":-38.109126,"median":-5.691463,"eighty":-3.066761,"marketCap":60882891},{"date":"2026-01-30","current":-1.869712,"twenty":-37.999948,"median":-5.513005,"eighty":-3.019747,"marketCap":47836557},{"date":"2026-02-06","current":-1.663573,"twenty":-37.887707,"median":-5.323443,"eighty":-2.9876,"marketCap":42562507},{"date":"2026-02-13","current":-1.638258,"twenty":-37.814908,"median":-5.250814,"eighty":-2.957395,"marketCap":41914817},{"date":"2026-02-20","current":-1.89141,"twenty":-37.791053,"median":-5.231258,"eighty":-2.930623,"marketCap":48391720},{"date":"2026-02-27","current":-1.591244,"twenty":-37.763222,"median":-5.212816,"eighty":-2.89957,"marketCap":40711963},{"date":"2026-03-06","current":-1.450202,"twenty":-37.64792,"median":-5.171192,"eighty":-2.886661,"marketCap":37103403},{"date":"2026-03-13","current":-1.565929,"twenty":-37.601604,"median":-5.067362,"eighty":-2.872563,"marketCap":40064273},{"date":"2026-03-20","current":-1.452342,"twenty":-37.462974,"median":-5.060142,"eighty":-2.848327,"marketCap":39164381},{"date":"2026-03-27","current":-1.345905,"twenty":-37.39506,"median":-5.023312,"eighty":-2.81779,"marketCap":36294178},{"date":"2026-04-02","current":-1.373373,"twenty":-37.39506,"median":-5.008257,"eighty":-2.777444,"marketCap":37034876},{"date":"2026-04-10","current":-1.383673,"twenty":-37.352614,"median":-4.96552,"eighty":-2.744896,"marketCap":37312637},{"date":"2026-04-17","current":-1.369939,"twenty":-37.352614,"median":-4.878764,"eighty":-2.677991,"marketCap":36942288},{"date":"2026-04-24","current":-1.321871,"twenty":-37.289369,"median":-4.834638,"eighty":-2.621936,"marketCap":35646068},{"date":"2026-05-01","current":-1.266936,"twenty":-37.075389,"median":-4.791246,"eighty":-2.520675,"marketCap":34164673},{"date":"2026-05-08","current":-1.304704,"twenty":-37.013045,"median":-4.759848,"eighty":-2.379633,"marketCap":35183132},{"date":"2026-05-15","current":-1.29097,"twenty":-36.657918,"median":-4.726862,"eighty":-1.989055,"marketCap":34812783},{"date":"2026-05-22","current":-0.952489,"twenty":-36.618159,"median":-4.701084,"eighty":-1.869712,"marketCap":28609441},{"date":"2026-05-29","current":-0.967902,"twenty":-36.524547,"median":-4.684546,"eighty":-1.778577,"marketCap":29072377},{"date":"2026-06-05","current":-0.961737,"twenty":-36.333397,"median":-4.581202,"eighty":-1.73518,"marketCap":28887203},{"date":"2026-06-12","current":-0.752128,"twenty":-36.234746,"median":-4.538149,"eighty":-1.677316,"marketCap":22591274},{"date":"2026-06-18","current":-1.174429,"twenty":-36.1867,"median":-4.529194,"eighty":-1.658046,"marketCap":35275719},{"date":"2026-06-26","current":-1.508594,"twenty":-36.138654,"median":-4.51746,"eighty":-1.640428,"marketCap":45312880},{"date":"2026-07-02","current":-1.661705,"twenty":-35.994244,"median":-4.482916,"eighty":-1.622122,"marketCap":49911799},{"date":"2026-07-10","current":-1.684222,"twenty":-35.726787,"median":-4.41968,"eighty":-1.609687,"marketCap":50588111},{"date":"2026-07-17","current":-1.414026,"twenty":-35.527938,"median":-4.351268,"eighty":-1.601689,"marketCap":42472371},{"date":"2026-07-24","current":-1.202372,"twenty":-35.095242,"median":-4.262561,"eighty":-1.59587,"marketCap":36115042},{"date":"2026-07-31","current":-1.134823,"twenty":-34.627571,"median":-4.241728,"eighty":-1.588961,"marketCap":34086107},{"date":"2026-08-07","current":-1.242902,"twenty":-34.501534,"median":-4.181454,"eighty":-1.572341,"marketCap":37332403},{"date":"2026-08-14","current":-1.459615,"twenty":-34.113333,"median":-4.141074,"eighty":-1.56639,"marketCap":44298951},{"date":"2026-08-21","current":-1.275295,"twenty":-34.018436,"median":-4.117333,"eighty":-1.548892,"marketCap":38704885}],"updateTime":1787567224709},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CRVO\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2620723420","title":"Chardan Raises Price Target on CervoMed to $21 From $15, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2620723420","media":"MT Newswires Live","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620723420?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:24","pubTimestamp":1773829491,"startTime":"0","endTime":"0","summary":"CervoMed (CRVO) has an average rating of buy and mean price target of $22.14, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620401340","title":"CervoMed price target lowered to $11 from $19 at Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2620401340","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620401340?lang=en_us&edition=fundamental","pubTime":"2026-03-18 07:00","pubTimestamp":1773788426,"startTime":"0","endTime":"0","summary":"Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on CervoMed (CRVO) to $11 from $19 and keeps a Buy rating on the shares....","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cervomed-price-target-lowered-to-11-from-19-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cervomed-price-target-lowered-to-11-from-19-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620640957","title":"Chardan Capital Sticks to Their Buy Rating for CervoMed (CRVO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620640957","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620640957?lang=en_us&edition=fundamental","pubTime":"2026-03-18 06:35","pubTimestamp":1773786922,"startTime":"0","endTime":"0","summary":"In a report released today, Daniil Gataulin from Chardan Capital maintained a Buy rating on CervoMed, with a price target of $21.00. According to T...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/chardan-capital-sticks-to-their-buy-rating-for-cervomed-crvo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/chardan-capital-sticks-to-their-buy-rating-for-cervomed-crvo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620409623","title":"CervoMed price target raised to $21 from $15 at Chardan","url":"https://stock-news.laohu8.com/highlight/detail?id=2620409623","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620409623?lang=en_us&edition=fundamental","pubTime":"2026-03-18 06:25","pubTimestamp":1773786346,"startTime":"0","endTime":"0","summary":"Chardan raised the firm’s price target on CervoMed (CRVO) to $21 from $15 and keeps a Buy rating on the shares. The neflamapimod program is fully b...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cervomed-price-target-raised-to-21-from-15-at-chardan-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cervomed-price-target-raised-to-21-from-15-at-chardan-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620180405","title":"CervoMed Reports 2025 Results, Advances Neflamapimod Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2620180405","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620180405?lang=en_us&edition=fundamental","pubTime":"2026-03-18 05:04","pubTimestamp":1773781497,"startTime":"0","endTime":"0","summary":"CervoMed ( ($CRVO) ) has shared an update. On March 17, 2026, CervoMed reported fourth quarter and full-year 2025 results alongside updates on its ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cervomed-reports-2025-results-advances-neflamapimod-programs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cervomed-reports-2025-results-advances-neflamapimod-programs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620040351","title":"CervoMed FY2025 net loss rose 66.67% to USD 27 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620040351","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620040351?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:35","pubTimestamp":1773779716,"startTime":"0","endTime":"0","summary":"CervoMed filed a Form 8-K reporting fourth-quarter and full-year 2025 results and corporate updates. Cash, cash equivalents and marketable securities were USD 20.9 million at Dec. 31, 2025, and the company said this is expected to fund operating expenses and capital expenditure for about six months. Full-year grant revenue fell 59% to USD 4 million, reflecting the completion of the randomized phase of the RewinD-LB trial in late 2024 and the extension phase in mid-2025. Full-year R&D expenses rose 16% to USD 21.8 million, driven by higher personnel and consulting costs, CMC work tied to RewinD-LB batch issues and pre-Phase 3 manufacturing improvements, and expenses for the RAS and nfvPPA trials initiated in 2025. Full-year net loss widened to USD 27 million and G&A expenses increased to USD 10.5 million, while CEO John Alam said CervoMed plans to initiate a single global Phase 3 DLB trial in the second half of 2026 subject to funding and expects multiple catalysts in the second half of","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL9TY297:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620424336","title":"BRIEF-CervoMed Reports Fourth Quarter And Full Year 2025 Financial Results And Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2620424336","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620424336?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:07","pubTimestamp":1773749241,"startTime":"0","endTime":"0","summary":"BRIEF-CervoMed Reports Fourth Quarter And Full Year 2025 Financial Results And Provides Corporate UpdatesMarch 17 (Reuters) - CervoMed Inc CRVO.O:CERVOMED REPORTS FOURTH QUARTER AND FULL YEAR 2025 FIN","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nTUA2GTFVB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620212364","title":"CervoMed: Compelling Neflamapimod Opportunity and Undervalued Shares Despite Near-Term Funding Overhang","url":"https://stock-news.laohu8.com/highlight/detail?id=2620212364","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620212364?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:55","pubTimestamp":1773748516,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Sumant Kulkarni from Canaccord Genuity maintained a Buy rating on CervoMed, with a price target of $27.00. Sumant K...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cervomed-compelling-neflamapimod-opportunity-and-undervalued-shares-despite-near-term-funding-overhang-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cervomed-compelling-neflamapimod-opportunity-and-undervalued-shares-despite-near-term-funding-overhang-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620838421","title":"CervoMed Q4 EPS $(0.88) Misses $(0.63) Estimate, Sales $8.726M Beat $966.667K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2620838421","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620838421?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:43","pubTimestamp":1773747794,"startTime":"0","endTime":"0","summary":"CervoMed (NASDAQ:CRVO) reported quarterly losses of $(0.88) per share which missed the analyst consensus estimate of $(0.63) by 40.13 percent. This is a 10 percent decrease over losses of $(0.80) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51292056/cervomed-q4-eps-0-88-misses-0-63-estimate-sales-8-726m-beat-966-667k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620142949","title":"Press Release: CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2620142949","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620142949?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:30","pubTimestamp":1773747000,"startTime":"0","endTime":"0","summary":"Reported positive Phase 2b RewinD-LB clinical data at CTAD 2025; additional analyses to be presented at AD/PD 2026. Obtained alignment with FDA and global regulators for planned Phase 3 trial design in patients with DLB and selected Phase 3 formulation, dose and dosing regimen. Multiple potential catalysts anticipated in the second half of 2026, including initiation of the planned Phase 3 trial, topline data from Phase 2a ischemic stroke recovery trial, initial topline data from Phase 2a primary progressive aphasia trial, and initiation of EXPERTS-ALS trial in Amyotrophic Lateral Sclerosis. BOSTON, March 17, 2026  -- CervoMed Inc. , a clinical-stage biotechnology company developing treatments for age-related brain disorders , today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided corporate updates.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","BK4097","BK4205","LU0240878834.USD","LU0240877869.USD","BK4139","BK4233","LU0345774631.USD","LU0348723411.USD","LU0205193047.USD","UK","LU0205194284.USD","BK4528","DLB","LU0345774391.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620423474","title":"CervoMed: Validated Phase 2b Data, De-Risked Pivotal Pathway, and Solid Cash Runway Underpin Reiterated Buy and $25 Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2620423474","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620423474?lang=en_us&edition=fundamental","pubTime":"2026-03-17 18:16","pubTimestamp":1773742577,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on CRVO stock, giving a Buy rating on March 5. Ram Selvaraju has given hi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cervomed-validated-phase-2b-data-de-risked-pivotal-pathway-and-solid-cash-runway-underpin-reiterated-buy-and-25-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cervomed-validated-phase-2b-data-de-risked-pivotal-pathway-and-solid-cash-runway-underpin-reiterated-buy-and-25-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620221495","title":"CervoMed Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2620221495","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620221495?lang=en_us&edition=fundamental","pubTime":"2026-03-17 03:16","pubTimestamp":1773688560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRVO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 16, 2026 15:16 ET (19:16 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619466627","title":"CervoMed Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2619466627","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619466627?lang=en_us&edition=fundamental","pubTime":"2026-03-16 21:31","pubTimestamp":1773667901,"startTime":"0","endTime":"0","summary":"CervoMed Inc reports results for the quarter ended December 31 - Earnings SummaryCervoMed Inc CRVO.OQ reported a quarterly adjusted loss of 88 cents per share for the quarter ended December 31, lower ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nL8N4041AG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619038177","title":"Manufacturing and Formulation Changes Threaten Cervomed’s Neflamapimod Development Timeline and Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2619038177","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619038177?lang=en_us&edition=fundamental","pubTime":"2026-03-15 14:01","pubTimestamp":1773554519,"startTime":"0","endTime":"0","summary":"Cervomed Inc. (CRVO) has disclosed a new risk, in the Manufacturing category. Cervomed Inc. faces the risk that changes in manufacturing methods or...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/manufacturing-and-formulation-changes-threaten-cervomeds-neflamapimod-development-timeline-and-costs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/manufacturing-and-formulation-changes-threaten-cervomeds-neflamapimod-development-timeline-and-costs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619143825","title":"Cervomed FY2025 net loss widened 66% to USD 26.97 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2619143825","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619143825?lang=en_us&edition=fundamental","pubTime":"2026-03-14 05:02","pubTimestamp":1773435771,"startTime":"0","endTime":"0","summary":"Cervomed reported a FY 2025 net loss of USD 26.97 million, widening 66%. FY 2025 grant revenue was USD 4.01 million, down 59% due to completion of the randomized phase of the RewinD-LB trial in late 2024 and the extension phase in mid-2025. FY 2025 research and development expense rose 16% to USD 21.82 million, driven by higher headcount and consulting costs, increased CMC work tied to RewinD-LB batch-issue analysis and pre-Phase 3 manufacturing improvements, and higher non-DLB clinical work including the RESTORE trial in recovery after stroke and a Phase 2a trial in nfvPPA. FY 2025 general and administrative expense increased 14% to USD 10.48 million, primarily reflecting higher personnel costs including severance. Cervomed ended FY 2025 with cash, cash equivalents and marketable securities of about USD 20.9 million and said it does not expect this to fund operating needs for at least 12 months from issuance of the financial statements.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDLSHcLK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619148150","title":"Top News Today: Stocks Fall, Oil Prices Rise as Iran Conflict Drags On","url":"https://stock-news.laohu8.com/highlight/detail?id=2619148150","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619148150?lang=en_us&edition=fundamental","pubTime":"2026-03-14 04:40","pubTimestamp":1773434400,"startTime":"0","endTime":"0","summary":"TREASURYS: Markets remained volatile, but Treasury traders took a breather with yields little changed across the curve. Yields declined a bit at the shorter end, while longer yields rose slightly.COMMODITIES: Oil futures settled higher and posted strong weekly gains. WTI settled up 3.1% at $98.71 a barrel for an 8.6% weekly gain. Brent rose 2.7% to $103.14, up 11% from a week ago.More Marines and Warships Head to Middle East as Hormuz Mission Intensifies. Inflation measured by the personal-consumption expenditures price index was 2.8% in the first month of 2026, a slight decline from December, the Commerce Department said Friday. Excluding volatile food and energy prices, core PCE inflation, often looked at as a gauge of underlying price trends, was 3.1%, up slightly from 3% in December.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["US3Y.BOND","BK4139","BK4588","LU0052756011.USD","BK4131","LU0251131958.USD","BK4533","CMTL","US30Y.BOND","ANNX","AP","BK4150","US12M.BOND","CRVO","US10Y.BOND","LIDR","TLTW","US5Y.BOND","LU1571399168.USD","FDX","AGEN","LU1267930227.SGD","LU0128525689.USD","US7Y.BOND","CTGO","BK4585","BK4157","LU0048573561.USD","US6M.BOND","US2Y.BOND","LU0310800965.SGD","BK4006","LU0251142724.SGD","TMF","BK4168","LU0742534661.SGD","BALY","BK4020"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2619148395","title":"Top News Today/Canada: Unemployment Rate Rises to 6.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619148395","media":"Dow Jones","labels":["economic"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619148395?lang=en_us&edition=fundamental","pubTime":"2026-03-14 04:30","pubTimestamp":1773433800,"startTime":"0","endTime":"0","summary":"Employment Dropped in February, Lifting Jobless Rate to 6.7%. Canada's job market has had a dismal start to the year, with employers shedding jobs two months running to buoy an unemployment rate that had been heading lower.That was much weaker than slight 10,000 gain in employment economists were expecting, and with more people searching for work the jobless rate pushed up 0.2 percentage point to 6.7%.Carney Tries to Put Dismal Data in Context  Biggest Job Loss in Year Nearly All in Private Sector  Weak Canadian Job Data Seen Sidelining Rate Hike Talk. The Montreal-based engineering- and infrastructure-services company said that the Toronto Stock Exchange approved its plans to launch a normal course issuer bid to buy back up to about 13.6 million shares for cancellation.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","GNE","BK4081","KLTR","BK4150","AGEN","BK4585","BK4539","BALY","BK4102","BK4009","BK4504","LU1035773651.USD","CYCN","HFFG","HHS","LU1069347547.HKD","AP","BK4155","LU0006061336.USD","BK4082","BK4157","DLTR","ANNX","BK4196","DCGO","BK4020","BK4114","CTMX","BK4588","LIDR","CTGO","CMTL","BK4139","GUTS","BK4023","BK4168","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619197687","title":"CervoMed Inc  expected to post a loss of 72 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2619197687","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619197687?lang=en_us&edition=fundamental","pubTime":"2026-03-13 20:50","pubTimestamp":1773406213,"startTime":"0","endTime":"0","summary":"CervoMed Inc  expected to post a loss of72cents a share - Earnings Preview CervoMed Inc CRVO.OQ CRVO.O is expected to  show a fall in quarterly revenue when it reports  results on March 16 (estimated)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nL8N40117E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618136649","title":"CervoMed to present neflamapimod data and host a dementia with Lewy bodies symposium at AD/PD 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2618136649","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618136649?lang=en_us&edition=fundamental","pubTime":"2026-03-12 19:04","pubTimestamp":1773313497,"startTime":"0","endTime":"0","summary":"CervoMed will attend the AD/PD 2026 Scientific Conference in Copenhagen, Denmark, on March 17-21, 2026. An oral presentation titled “Neflamapimod Treatment Effects In Patients With Dementia With Lewy Bodies Without Concomitant AD Pathology In The Rewind-LB Clinical Study ” is scheduled for March 21, 2026 at 14:25-14:40 CET in Auditorium 10. CervoMed will also sponsor a scientific symposium titled “From Mechanisms to Medicines: Advancing Drug Development in Dementia With Lewy Bodies” on March 20, 2026 at 16:20 CET in Hall A1.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL4RWkbD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","SG9999014005.SGD","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU2095319765.USD","LU2210150020.SGD","SG9999014021.USD","NDAQ","LU2210149790.SGD","SG9999014039.USD","CRVO","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4585","BK4139","BK4588","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618361401","title":"CervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2618361401","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618361401?lang=en_us&edition=fundamental","pubTime":"2026-03-12 19:00","pubTimestamp":1773313200,"startTime":"0","endTime":"0","summary":"Data further support choice of patient population and dosing regimen in CervoMed's planned Phase 3 trial in dementia with Lewy bodies (DLB) DLB is the second most common progressive dementia, affectin","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/12/3254471/0/en/CervoMed-Announces-Presentations-at-Upcoming-AD-PD-2026-Scientific-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","CRVO","BK4528","BK4233","LU0345774631.USD","BK4139","BK4023","LU1169589451.USD","LU0345774391.USD","DLB","AD","LU0205194284.USD","PD","LU0348723411.USD","LU0240877869.USD","BK4205","BK4097","LU0240878834.USD","LU0205193047.USD","LU1169590202.USD","UK"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":6,"totalSize":128,"code":"91000000","status":"200"}]}}